Current Research & Innovations

Tumor Vaccines

• Lung Cancer: Vaccination with NYLESO-1 Recombinant Protein combined with Nontanide-51 —Vaccination with NYLESO-1 Recombinant Protein combined with Nontanide-51 as Immunotherapy Strategy for Lung Cancer Patients ( , )
• Metastatic Cancer: Comparing the IntraLesional rF-B7.1 and rF-TRICOM Vaccines —This study compares the effectiveness of two vaccines, IntraLesional rF-B7.1 and rF-TRICOM, in the treatment of metastatic cancer. (Howard Kaufman, MD)
• Metastatic Cancer: Evaluating the Effect of High Dose Interleukin-2 Therapy on Peripheral Blood CD4+ CD25+ Regulatory T Cells —This study evaluates the effect of high dose Interleukin-2 therapy on peripheral blood CD4+ CD25+ regulatory T Cells in metastatic cancer patients. (Howard Kaufman, MD)
• Metastatic Melanoma: Evaluating a Treatment of Sequential High-Dose Interleukin-2 Followed by Temozolomide and GM-CSF (Phase II) —This phase II study evaluates sequential high-dose Interleukin-2 followed by temozolomide and GM-CSF as a treatment for metastatic melanoma. (Howard Kaufman, MD)
• PANVAC™ - VF in Combination with GM-CSF —A Phase III Randomized, Controlled Study to Evaluate the Safety and Efficacy of PANVAC™ - VF in Combination with GM-CSF Versus Best Supportive Care or Palliative Chemotherapy in Patients with (Howard Kaufman, MD)
• recMAGE Immunotherapy Trial —A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer ( , )
• Renal Cell Cancer Treatment: Evaluating TroVax in Conjunction with Interleukin-2 (IL-2) —A preliminary study of the safety, immunogenicity, and clinical efficacy of TroVax given in conjunction with Interleukin-2 (IL-2) in the treatment of stage IV renal cell cancer. (Howard Kaufman, MD)
• Stage III or IV Melanoma: Comparing MDX-010 in Combination with a Melanoma Vaccine with Melanoma Vaccine Alone —This randomized, two-stage, multicenter study compares two treatments for HLA-A*0201-positive patients with previously treated unresectable stage III or IV melanoma: MDX-010 in combination with a melanoma vaccine, and a melanoma vaccine alone. (Howard Kaufman, MD)
• Stage III or IV Melanoma: Evaluating Multiple Doses of Ipilimumab (MDX10) Monotherapy (Phase II) —This randomized, double-blind, multi-centered phase II fixed-dose study evaluates multiple doses of ipilimumab (MDX10) monotherapy in patients with previously treated unresectable stage III or IV melanoma. (Howard Kaufman, MD)
• Stage IIIc and IV Malignant Melanoma: Evaluating the Efficacy, Safety, and Immunogenicity of OncoVEX (Phase II) —This phase II study evaluates the efficacy, safety, and immunogenicity of OncoVEX in patients with stage IIIc and IV malignant melanoma. (Howard Kaufman, MD)